Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

1091 - 1100 of 3501 results found

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Agents Targeting Lymphoid Cells Surface Antigens [I]: CD19, CD20 and CD52)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and mTOR Inhibitors)

MeSH Terms
Biological Therapy (E02.095); Protein-Tyrosine Kinases (D08.811.913.696.620.682.725); Receptor Protein-Tyrosine Kinases (D08.811.913.696.620.682.725.400); Receptor Protein-Tyrosine Kinases (D12.776.543.750.060); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Soluble Immune Effector Molecules [I]: Anti-Tumor Necrosis Factor-α Agents)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480); Tumor Necrosis Factor-alpha (D23.529.374.500.800); Tumor Necrosis Factor-alpha (D12.776.467.374.750.626); Tumor Necrosis Factor-alpha (D12.644.276.374.750.626); Tumor Necrosis Factor-alpha (D23.529.374.750.626); Tumor Necrosis Factor-alpha (D12.776.467.972.626); Tumor Necrosis Factor-alpha (D12.644.276.972.626); Tumor Necrosis Factor-alpha (D23.529.972.626)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

Establecimiento de estándares, registro y análisis de casos de tratamiento de la colitis ulcerosa mediante sistemas de aféresis (Informe nº: Osteba E-08-05)

MeSH Terms
Colitis; Ulcerative (C06.405.469.158.188.231); Leukapheresis (E02.095.160.570); Blood Component Removal (E02.120)
Guideline Contact
Nora Ibargoyen Roteta (nibargoyen@bioef.org)
English Title Translation
Establishing standards, records and analytical procedures for the treatment of ulcerative colitis
Publication Scope
management
Countries of Application
Spain
Guideline Publication Status
Published
Languages
Spanish
Authors
OSTEBA (ES)
Publication Year
2008